July 2025 in “World Journal of Stem Cells” This review highlights that exosome-based therapies show promise for hair regeneration by modulating signaling pathways and enhancing hair follicle regeneration; however, further clinical research is needed due to variability in methods and limited clinical studies.
This study observed that a combination of sinapic acid and glabridin from Zhimo herbal extract improved hair growth and reduced oxidative stress in a DHT-induced model of androgenetic alopecia in mice by preventing ferroptosis and stabilizing β-Catenin, offering potential application for AGA treatment.
April 2025 in “Antioxidants” In this study, the researchers found that the water-soluble fraction of Rhus semialata gall extract and its component Penta-O-Galloyl-β-D-Glucose promoted hair growth in human dermal papilla cells, and clinical trials supported these findings, showing improved hair density and appearance compared to placebo.
January 2025 in “Applied Sciences” This review examines sulforaphane's interactions with hormone-mediated health conditions, focusing on gender-specific health issues, but reports no new original research findings.
November 2024 in “International Journal of Molecular Sciences” This study developed caffeine-loaded nanoparticles coated with ultradeformable liposomes for better hair follicle delivery, showing non-cytotoxicity and potential to reduce oxidative stress in DHT-damaged cells, suggesting an alternative treatment for androgenetic alopecia.
March 2024 in “Cell communication and signaling” This study found that sleep deprivation in mice can trigger prostatitis by activating the cGAS-STING pathway due to reduced levels of dihydrotestosterone and melatonin, resulting in a pro-inflammatory environment, while recovery sleep can mitigate these effects.
March 2024 in “Bioactive Materials” This study found that modifying adipose-derived stem cells to overexpress the adhesion protein JAM-A increased the adhesion and resilience of dermal papilla cells in the context of androgenic alopecia, potentially facilitating hair regrowth despite challenges such as damage from dihydrotestosterone and macrophages.
February 2024 in “Biomedicines” This review examines the hormonal causes of hair loss, noting how androgen excess can lead to follicle miniaturization and linking estrogen deficiency and thyroid dysfunction to common alopecia types. It further discusses hormonal treatments such as finasteride, dutasteride, and spironolactone.
December 2023 in “Regenerative therapy” In this review, the authors reported that exosomal miRNA-based therapies showed promising therapeutic effects on nine skin diseases in animal models, with enhanced outcomes observed when using miRNA-overexpressing exosomes compared to natural ones; however, no comparisons to standard treatments were available.
December 2023 in “Scientific Reports” In this study, researchers successfully established immortalized human frontal and occipital scalp dermal papilla cell lines from androgenetic alopecia patients, observing distinct gene expression, androgen receptor levels, and hair follicle growth effects between these regions, which may help advance hair loss research and therapeutic development.
October 2023 in “Journal of Cosmetic Dermatology” This study found that an octapeptide binding to Lgr5 can enhance the proliferation and differentiation of human primary hair cells by activating the Wnt/β-catenin signaling pathway, suggesting its potential as a treatment for hair loss in androgenetic alopecia.
January 2023 in “Theranostics” This study reported that a curcumin-zinc microneedle patch improved hair regrowth and wound healing in animal models, suggesting potential as a versatile treatment for hair loss.
March 2023 in “International Journal of Molecular Sciences” This study found that exosomes from adipose mesenchymal stromal cells, particularly those carrying miR-122-5p, may enhance hair follicle regeneration in androgenic alopecia by targeting the TGF-β/SMAD3 axis.
December 2022 in “Scientific Reports” This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.
January 2022 in “Biomedical Reports” This study suggests that inaudible sound at 30 kHz may promote hair growth and inhibit hair loss signals in human dermal papilla cells, indicating potential as a new treatment for androgenic alopecia.
24 citations
,
March 2002 in “Expert opinion on investigational drugs” This review discusses various anti-androgen treatments for hirsutism, including androgen receptor blockers and inhibitors, and emphasizes the role of diagnosis in selecting the most appropriate therapy, but reports no new clinical results.
19 citations
,
April 2020 in “Dermatologic Therapy” This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.
6 citations
,
November 2010 in “International Journal of Andrology” In a clinical trial, this study found that a modified slow-release oral testosterone formulation improved pharmacokinetics, delaying serum testosterone peaks and reducing serum DHT compared to immediate-release formulations, especially when combined with finasteride.
5 citations
,
September 2017 in “Plastic and Aesthetic Research” This study aimed to assess whether using minoxidil alongside nutritional cyclical supplements could boost hair regrowth without antiandrogens or enzyme blockers, focusing on hair root strengthening. Results are not reported.
11 citations
,
January 1995 in “Biomedicine & pharmacotherapy” This review discusses the use of finasteride and alpha antagonists for symptomatic benign prostatic hypertrophy and suggests current studies are evaluating combination therapies as potential non-surgical alternatives.
April 2025 in “Drug Design Development and Therapy” This study observed that the herbal extract WJWE promoted hair growth and protected hair follicle cells in a DHT-induced murine model of androgenetic alopecia, potentially by engaging the SIRT1/JNK/p38 MAPK and Wnt5A/β-Catenin signaling pathways.
27 citations
,
August 1999 in “Urology” This study found that finasteride improved urodynamic measures of obstruction in men with benign prostatic enlargement and lower urinary tract symptoms, with continued improvement over two years of treatment.
1 citations
,
January 2019 in “Advances in Medical Sciences” This study found that a combination of azelaic acid, minoxidil, and caffeine significantly reduced skin flap necrosis in rats, likely by increasing nitric oxide content and iNOS expression, compared to individual treatments.
4 citations
,
January 1982 in “Endocrinologia Japonica” This study found that castration increased 5 alpha-reductase activity in the sebaceous glands of male hamsters, but administering testosterone propionate or 5 alpha-dihydrotestosterone inhibited this effect.
78 citations
,
August 2012 in “Human molecular genetics online/Human molecular genetics” This study found that three genetic loci, including the newly identified JMJD1C, are associated with circulating testosterone and dihydrotestosterone levels, explaining a small portion of their variance in European men.
3 citations
,
March 2018 in “European Urology Supplements” This study found that Finnish men using 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had improved disease-specific survival compared to non-users, suggesting potential benefits of the treatment.
January 2019 in “ISGE series” This study found that estradiol and other sex steroids reduced the capture of monocytes by human endothelial cells in vitro, potentially inhibiting the formation of atherosclerosis by promoting nCAM polysialylation, which interferes with leukocyte tethering to the vascular endothelium.
January 2022 in “Galenika Medical Journal” This article reviews the management of lower urinary tract symptoms, highlighting drug therapy advancements that have reduced the frequency of surgical interventions.
This chapter reviews pharmacodynamic evaluations in endocrine disorders focusing on oral antidiabetics, insulin analogues, and hormone interactions, but reports no new results.
November 2024 in “Journal of Family Medicine and Primary Care” This review highlights that 5 Alpha Reductase Inhibitors, used for treating conditions like benign prostatic hypertrophy, can cause side effects that sometimes persist after stopping the medication, urging physicians to consider these drugs as potential sources of new symptoms in patients.